Supply Chain | November 27, 2021
Pharma firms switch to advanced pharma manufacturing
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
The company is moving towards complex and more differentiated products
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
Launching in 2022, its availability will be expanded to the global market
Subscribe To Our Newsletter & Stay Updated
